.png){kind=icon}
.png){kind=icon}
Return
Mid-Term Outcomes of Balloon-Expandable Aortic Valve-in-Valve Replacement in the United States
.png){kind=icon}
OA
AI
A
A
V
A
P
I
G
R
M
E
J
J
V
V
S
T
DOI：10.1016/j.jcin.2025.06.039.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Aortic valve-in-valve (AViV) replacement for is approved for patients with degenerated surgical valves at high or prohibitive surgical risk, mostly on the basis of small series with short-term follow-up.
Keywords:
aortic valve-in-valve
bioprosthesis
surgical valve
transcatheter aortic valve replacement
AViV
aortic valve-in-valve
AVR
aortic valve replacement
BEV
balloon-expandable valve
BVF
bioprosthetic valve fracture
CMS
Centers for Medicare and Medicaid Services
FDA
U.S. Food and Drug Administration
PROM
Predicted Risk of Mortality
S3
SAPIEN 3
S3U
SAPIEN 3 Ultra
S3UR
SAPIEN 3 Ultra RESILIA
SAVR
surgical aortic valve replacement
STS
Society of Thoracic Surgeons
TAVR
transcatheter aortic valve replacement
THV
transcatheter heart valve
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
11.4
Papers:
8.3K
Citations:
1.8W
Organization
Cited Papers